



Reference number
4697-A

Aetna Medicare Part B Drug Criteria

Ilumya

This policy is for Aetna Medicare members. [Find the Aetna Commercial Medical Drug Criteria.](#)

For Aetna Medicare members, National Coverage Determinations (NCDs) and Local Coverage Determinations (LCDs) will be applied to Part B drug requests when applicable. Aetna Medicare Part B Drug Criteria documents will be used in the absence of an NCD and LCD.

POLICY

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Ilumya	tildrakizumab-asmn

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

FDA-Approved Indication¹

Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

All other indications will be assessed on an individual basis. Submissions for indications other than those listed in the coverage criteria should be accompanied by supporting evidence from Medicare approved compendia.

Documentation

The following documentation must be available, upon request, for all submissions:



Reference number
4697-A

Continuation requests

Chart notes or medical record documentation supporting benefit of therapy.

Coverage Criteria

Plaque psoriasis¹⁻⁴

Authorization of 12 months may be granted for the treatment of moderate to severe plaque psoriasis.

Continuation of Therapy

All members (including new members) requesting authorization for continuation of therapy must be currently receiving therapy with the requested agent.

Authorization for 12 months may be granted when all of the following criteria are met:

- The member is currently receiving therapy with Ilumya.
- Ilumya is being used to treat an indication listed in the coverage criteria.
- The member is receiving benefit from therapy.

Summary of Evidence

The contents of this policy were created after examining the following resources:

- The prescribing information for Ilumya.
- The available compendium
 - National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium
 - Micromedex DrugDex
 - American Hospital Formulary Service- Drug Information (AHFS-DI)
 - Lexi-Drugs
 - Clinical Pharmacology
- Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents.
- Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.
- Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics.
- Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies.

After reviewing the information in the above resources, the FDA-approved indication listed in the prescribing information for Ilumya is covered.

Explanation of Rationale

Support for FDA-approved indications can be found in the manufacturer’s prescribing information.

References

1. Ilumya [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; April 2024.
2. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 4: Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61(3):451-485.
3. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65(1):137-174.
4. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029-1072.
5. Menter A, Gelfand JM, Connor C, et al. Joint AAD-NPF guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445-1486.

CPT Codes / HCPCS Codes / ICD-10 Codes

Code	Description
Other CPT codes related to the CPB:	
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
HCPCS codes covered if selection criteria are met:	
J3245	Injection, tildrakizumab, 1 mg
ICD-10 codes covered if selection criteria are met:	
L40.0	Psoriasis vulgaris [Plaque psoriasis] [moderate to severe]



Reference number
4697-A

Revision History

Date	Version	Update	Revisions
01/01/2024	2023a	New Criteria	Policy effective.
10/01/2024	2024	Criteria Change	For continuation of therapy, updated to member is receiving benefit from therapy. For documentation section, updated to chart notes or medical record documentation supporting benefit of therapy.
07/31/2025	2025	Annual Review	Medicare Utilization Management Committee approved.

See Evidence of Coverage for a complete description of plan benefits, exclusions, limitations and conditions of coverage. Plan features and availability may vary by service area.